Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Doxorubicin in Neoadjuvant High-grade STS
NCT05747521Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in soft tissue sarcoma (STS), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate up to 60 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05747521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05747521.